ω-3酸乙酯(Trygg Pharma AS)(Omega-3-acid ethyl esters(Trygg Pharma AS)) - 药物靶点：Triglyceride_在研适应症：高脂血症，I型高脂蛋白血症，高甘油三酯血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lotriga Granular、Omega-3 fatty acid ethyl esters、OMEGA-3-ACID ETHYL ESTERS

+ [18]

靶点

Triglyceride

作用方式

调节剂

作用机制

甘油三酯调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Takeda Pharmaceutical Co., Ltd.Viatris Pty Ltd.Waylis Therapeutics LLC

非在研机构

GSK PlcPronova BioPharma ASA

Reliant Pharmaceuticals LLC

+ [9]

权益机构

Woodward Pharma Services LLC

GlaxoSmithKline LLC

最高研发阶段批准上市

首次获批日期

美国 (2004-11-10),

高甘油三酯血症

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C46H70O4

InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N

CAS号861006-80-6

关联

391

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床试验

ChiCTR2500111535

/ Recruiting临床2期

Omega-3CIPNII/A two-arm, open-label, multicenter phase II study on the efficacy and safety of omega-3 polyunsaturated fatty acids combined with levocarnitine in preventing chemotherapy-induced peripheral neuropathy in colorectal cancer patients receiving postoperative adjuvant chemotherapy regimens containing oxaliplatin

开始日期2025-11-01

申办/合作机构

江苏恒瑞医药股份有限公司

[+2]

NCT06434948

/ Enrolling by invitation临床2期IIT

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

开始日期2025-10-15

申办/合作机构

University of Missouri

NCT06478290

/ Not yet recruitingN/A

Pilot Assessment of the Safety of a Combination of Curcumin, Omega-3, and Vitamin D Supplements (PASCOD) in ACPA+ Individuals

The goal of this clinical trial is to determine if the level of Anti-cyclic citrullinated peptide antibody (ACPA) is altered after taking curcumin, omega-3, and vitamin D supplements (COD) for 3 months. It will also determine the safety and tolerability of COD in the study population. This trial aims to answer the following questions: Does COD consumption lower the level of ACPA in the study participants? What side effects will participants have after taking COD? This pilot study will have an open label pre-post design and study participants will know that they are using each of the three supplements. Participants will: Take the combination of supplements following an evening meal, for 84 consecutive days. Visit the clinic/study team twice during the study duration on days 0 and 84 for checkups and tests. Keep a diary of study treatment consumption.

开始日期2025-10-01

申办/合作机构

University of Manitoba

[+1]

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床结果

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的转化医学

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的专利（医药）

登录后查看更多信息

1,668

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的文献（医药）

2025-11-01·POULTRY SCIENCE

Cecal bacterial communities and lung immunity in layers fed omega-3 fatty acids or yeast bioactives under different space allowance

Article

作者: Diarra, Moussa S ; Clairmont, Lindsey ; Kiarie, Elijah G ; Waliaula, Paul Kibaba ; Lepp, Dion ; Yin, Xinhua

The poultry-rearing environment and diet can influence gut microbiota and immunity. However, the long-term effects of early-life nutritional interventions on gut heath in layers under various spacing allowances (SA) are not well understood. This study investigated how early-life dietary yeast bioactives (YB) or co-extruded full-fat flaxseed, a source of omega-3 fatty acids (N-3 FA), from placement to 16 weeks of age (woa) influenced the development of cecal microbiota and immune function in Lohmann LSL Lite pullets reared under different SA, with follow-up to 72 woa. The experiment involved 2,832 newly hatched chicks reared in an enriched cage system under high (HSA, 348 cm²/bird) or low (LSA, 284 cm²/bird) SA and fed either control diet (C), C + 3 % N-3 FA, or C + 0.05 % YB. Ceca were sampled at 4, 8, 16, 35, and 72 woa for bacterial plate counts, 16S rRNA sequencing, and short-chain fatty acid (SCFA) quantification. Lungs were analyzed for immune gene expression. At 4 and 16 woa, β-diversity (P = 0.01) revealed dissimilarity between the bacterial communities of birds under HSA and LSA groups. High Bacteroides abundances, propionic and iso-butyric acids concentrations were observed in LSA at both sampling points (P<0.05). At 16 woa, the highest and lowest n-butyrate concentrations were noted in N-3 FA- and control-fed birds, respectively (P < 0.05), regardless of SA. Barnesiellaceae positively correlated with n-valeric and acetic acid in N-3 FA-fed birds at 4 woa. In YB-fed pullets, Lactobacillaceae and Enterobacteriaceae showed a positive correlation with n-butyric acid. In the lungs, about 15 genes, including IL1β,IL2, and IL8, were differentially expressed depending on SA and diets (P<0.05). Early dietary YB or N-3 FA under different SA modulated cecal bacterial community diversity and structure, SCFA profiles, and enhanced lung immune responses in layer.

2025-11-01·FOOD CHEMISTRY

Fatty acid benefit and pesticide exposure risks via consumption of edible insects and other invertebrates in South China

Article

作者: Guo, Kaiying ; Sun, Chuansheng ; Zheng, Xiaobo ; Zhu, Yujing

Insects are promising food sources because of their high protein content, but the relationship between FA benefits and pesticide pollution of insects has not been well characterized. This study measured fatty acids and current-use pesticides (CUPs) in 20 edible insects and other invertebrate species from Yunnan, China. Total concentrations of the 15 main CUPs ranged from 0.87 to 443 ng/g dry weight for different species. The presence of palmitic acid and eicosapentaenoic acid was an indicator of bamboo-feeding species and aquatic insects, respectively. Underground species had significantly higher CUPs than overground and aquatic species (p < 0.01). α-linolenic acid was a potential ecological indicator of the levels of cymoxanil and difenoconazole. Propiconazole and imidacloprid in several species exceeded the maximum residue limits of CUPs in China. Aquatic invertebrates like crawling insect and leech were recommended as promising food in inland areas, because of the low CUP levels and high omega-3.

2025-11-01·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Lifelong dietary Omega-3, -6, and -9 ratios shape adult behavior and response to adolescent THC exposure in rats

Article

作者: Demars, Fanny ; Chaumette, Boris ; Marzo, Aude ; Kebir, Oussama ; Krebs, Marie-Odile ; Jay, Thérèse M ; Frajerman, Ariel ; Le Pen, Gwenaëlle ; Lamazière, Antonin

BACKGROUND:

Alterations in membrane lipids are well established in schizophrenia, and diet could be an accessible, modifiable etiological factor. We examined the influence of Polyunsaturated fatty acids (PUFAs) intake throughout the lifespan on behaviour in adult rats. We further explored a possible interaction with adolescent exposure to delta-9-tetrahydrocannabinol (THC), the lipidic psychoactive compound responsible for cannabis's psychotic effects.

METHODS:

Sprague Dawley rats (n = 164, male and female) were separated into 3 groups exposed from conception to specific diets enriched in omega 3, 6, or 9, controlled by gas chromatography, with ratios determined to stay close to physiological balance. They were explored in adulthood in tests acknowledged as modelling symptomatic dimensions of schizophrenia, including locomotor activity, short-term recognition memory, sensorimotor gating, social interactions, anxiety, impulsivity, response inhibition and attention.

RESULTS:

The effects of diet on social interactions, locomotor activity, anxiety, cognitive flexibility, response inhibition, and impulse control were significant. Omega-3-enriched diet rats were less anxious and more impulsive than those receiving an omega-6 diet. THC exposure in adolescence interacts with diet and gender to influence adult anxiety and impulsivity.

LIMITATIONS:

The diet's impacts are difficult to compare with previous data because we used new ratios of PUFA to be more physiological.

CONCLUSION:

These results underline the importance of considering the relative influence of the 3 different families of Unsaturated Fatty acids and the importance of the omega-6/omega-3 ratio in controlled and balanced diets. The results could explain why omega-3 supplementation has only a moderate effect at high dosages and/or possibly only in patients with an initial alteration in lipid membrane composition.

84

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的新闻（医药）

2025-08-18

·PRNewswire

ZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency - and why high-precision testing plus an enhanced formula can close the gap

GOTHENBURG, Sweden, Aug. 18, 2025 /PRNewswire/ -- A groundbreaking study published in Lipids in Health and Disease (9 August 2025) reveals that the vast majority of individuals worldwide have insufficient omega-3 levels, despite widespread supplement use, highlighting a critical global health need. The analysis, covering more than 590,000 whole-blood dried blood spot samples, was conducted using Zinzino's proprietary BalanceTest database – the world's largest of its kind to date. Key insights from the study: Widespread omega-3 deficiency: Across diverse regions, participants—including those reporting use of omega-3 supplements – frequently failed to reach optimal levels, with consistently elevated omega-6:3 ratios. Zinzino's omega-3 supplement BalanceOil+ was not part of the evaluation. Regional disparities: Coastal diets rich in seafood showed relatively higher omega-3 status, while inland regions with typical Western diets lagged behind. Testing is essential: These results validate the necessity of measuring rather than guessing – objective blood testing like the BalanceTest is crucial to evaluate nutritional status accurately and guide effective interventions. A powerful combination: Test-based nutrition + advanced delivery "This study is a milestone for us," says Dr. Colin Robertson, Chief Product Officer at Zinzino. "For the first time, we have published data in a peer-reviewed scientific journal – Lipids in Health and Disease – which has been a collaboration between our in-house research team, our Scientific Advisory Board, and the independent analytical contract lab Vitas AS. This is not just a publication; it's hard evidence that we are shaping global nutrition science with real-world evidence from a global population." "The world has moved beyond one-size-fits-all solutions. This study underscores that many supplements in the market fall short – and targeted, scientifically designed formulations paired with accurate, large-scale measurement are critical to closing the nutritional gap. "The BalanceTest provides a scientifically validated, standardized, and scalable method to assess omega-3 status and omega-6:3 balance – all from a simple dried blood spot sample. It delivers precise, reproducible results that allow both individuals and health professionals to track nutritional status and guide targeted, evidence-based interventions," Dr. Robertson concludes. Why this matters now While the study establishes an essential baseline for global omega3 status, the next frontier lies in improving supplementation. That's where Zinzino's BalanceOil comes in—a carefully crafted, proprietary blend (60% high-quality fish oil rich in EPA and DHA, 40% extra virgin olive oil), fortified with polyphenols, natural tocopherols, and vitamin D. This design enhances oxidative stability and bioavailability, aiming to support better omega-3 blood levels and balanced fatty acid ratios. With omega-3 levels tied to cognitive function, cardiovascular health, and inflammation control, the implications of this study are both clinical and strategic. Some populations eat fish regularly, others hardly at all. And while supplementation is promoted, the actual omega-3 status of individuals – and entire populations – has been largely unknown due to lack of objective measurement. Testing offers a roadmap: start with a scientific measurement (BalanceTest), follow up with a superior formulation (BalanceOil), and continue supplementing and testing to close the nutritional gap. Public health guidelines recommend higher intakes of omega-3, but diets vary enormously by culture and country. "Our results provide the most comprehensive picture to date of omega-6:3 balance worldwide," says Dr. Martina Torrissen, Research & Development Specialist at Zinzino and co-author of the article. "By identifying critical gaps, this research helps guide public health priorities and empowers companies like Zinzino to deliver personalized solutions that address real needs in global nutrition," Dr. Torrissen concludes. The motto 'Test, don't guess' is central to Zinzino's test-based nutrition philosophy and represents a leap forward in personalized health and wellness. "For Zinzino, this is more than science – it validates our mission," says CEO Dag Pettersen. "By combining personalized, test-based nutrition with one of the world's largest fatty acid databases, we are not only transforming individual lives but also shaping the future of preventive health on a global scale." "One of our greatest strengths is that the BalanceTest can literally measure the world," says Pettersen. "Unlike surveys or population samples based on blood plasma, which require complex lab work, we have developed a reliable, highly sensitive tool that measures people's health status — right from their own homes." About BalanceTest The BalanceTest is an at-home dried blood spot (DBS) test that delivers reliable readings of omega-3 status and fatty acid balance. Administered via a fingertip sample, it's processed by Vitas, an independent, GMP-certified lab in Oslo, Norway, delivering scientific clarity on health markers like Omega-3 index, cell membrane fluidity, and mental resilience. About BalanceOil BalanceOil+ is a purpose-built omega-3 supplement featuring a 60:40 fish oil plus extra virgin olive oil ratio, supplemented with vitamin D and natural tocopherols for enhanced stability and absorption, designed to help users achieve and sustain a balance of omega-6 and omega-3 blood levels linked with health benefits. About Zinzino Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, and Australia. Publication details Title: Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from >500,000 wholeblood dried blood spot samples Journal: Lipids in Health and Disease (2025), Article Number: 260 For more information: Dag Pettersen CEO Zinzino +47 (0) 932 25 700, [email protected] Pictures for publication free of charge: [email protected] Certified Adviser: DNB Carnegie Investment Bank AB (publ.) This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-06-09

·九洲药业

喜报!康川济医药助力合作伙伴二十碳五烯酸乙酯软胶囊获批上市

据NMPA发布的药品批准证明文件送达信息显示，新华制药的二十碳五烯酸乙酯软胶囊（0.5g和1.0g）取得国家药品监督管理局下发的《药品注册证书》，获得上市许可。康川济医药为该产品提供了研发相关服务。二十碳五烯酸乙酯软胶囊属于高纯度的Omega-3脂肪酸乙酯类药物，能够有效抑制肝脏中胆固醇的合成，降低血液中胆固醇和甘油三酯水平，进而达到降低血脂的目的。大量临床研究表明，其在控制血脂方面效果显著，在控制饮食的基础上，用于降低重度高甘油三酯血症（≥500mg/dL）成年患者的甘油三酯（TG）水平，4g /天的剂量应用 12 周，可降低甘油三酯水平约 16%-26% 。不仅如此，它还在心血管疾病预防方面展现出突出优势。发表于《新英格兰医学杂志》的重磅研究 REDUCE - IT 表明，对于他汀治疗后仍存在高甘油三酯血症的心血管疾病高危患者，使用二十碳五烯酸乙酯能显著降低主要不良心血管事件相对风险达25%。康川济医药南京康川济医药科技有限公司成立于2013年，浙江九洲药业股份有限公司(股票简称:九洲药业，股票代码: 603456.SH)的控股子公司，业务范围覆盖创新药、改良型新药、高端仿制药研发及技术咨询和代理注册等；研发团队150余人，硕士学历占比30%以上；研发设备配备齐全，满足新药开发各阶段要求。依托九洲药业，我们可以提供原料药+制剂的CDMO一站式服务。联系我们地址：南京市江宁区文芳路199号5幢二层商务合作：文章转载自南京康川济

申请上市

2025-06-05

·PRNewswire

Lupus Foundation of America Awards Summer Fellowship Grants to Seven Young Scientists Advancing Lupus Research

WASHINGTON, June 5, 2025 /PRNewswire/ -- The Lupus Foundation of America is proud to announce the seven recipients of the 2025 Gina M. Finzi Memorial Student Summer Fellowship Program (Finzi). This program supports undergraduate, graduate, and medical students conducting lupus-focused research under the guidance of experienced mentors at academic institutions in the US, Canada or Mexico. Its purpose is to inspire medical and graduate students to pursue lupus research, helping to build the future pipeline of experts across North America. This year's Finzi Fellows will spend the summer investigating unanswered questions in lupus including: How skin lesions heal – uncovering the biological steps the body takes to resolve lupus-related skin damage. The brain and nerves in lupus – exploring how lupus affects the brain, spinal cord, and nerves, including changes in brain structure and function. Mental health and self-care – studying how chronic stress from "superwoman schema" affects a patient's ability to engage in self-management. Lupus in the kidneys – identifying the biological and social factors that drive the development of lupus nephritis (lupus-related kidney disease), a serious kidney complication. The role of diet and nutrients – two studies in this area, examining how dietary compounds like omega-3 fatty acids influence immune cells and disease activity, as well as how nutrition may impact symptoms and flares. Lupus and the X chromosome – investigating how changes in genes located on the X chromosome may increase lupus risk, especially in women. "Students pursuing their graduate or medical education in biomedical fields are poised to become the next generation of scientists, and recognition of their efforts through the Gina M. Finzi Student Summer Fellowship Program, and the excitement for their research, helps inspire students to continue investigations in the field of lupus and autoimmunity in their future careers," shared Montserrat Anguera, PhD, Associate Professor, Department of Biomedical Sciences, University of Pennsylvania and 2025 Finzi grantee mentor. Throughout the fellowship, Finzi recipients work closely with seasoned clinical investigators and biomedical scientists who provide guidance and foster their development as emerging scientists. This mentorship is a vital part of the program, offering essential support as students begin to shape their careers in lupus research. Launched in 1984, the Gina M. Finzi Memorial Student Summer Fellowship Program was established in memory of Gina M. Finzi, daughter of former Lupus Foundation of America President Sergio Finzi, PhD. Many past fellows have gone on to become leaders in the field, advancing groundbreaking research in lupus. "The future of lupus research is in the hands of the students that will be ushering in the next breakthroughs in the field," shared Joy Buie, Ph.D, MSCR, RN, Vice President of Research at Lupus Foundation of America. "The Gina M. Finzi Memorial Student Summer Fellowship Program is uniquely positioned to ensure investments are made in the brightest, most innovative young minds. With guidance from mentors, these Finzi Fellows will gain the experiences needed to support a research career focused on closing gaps in lupus diagnosis, treatment and care." The research conducted by Finzi Fellows will contribute to a variety of crucial areas within the lupus field: Grace Crossland Dartmouth College, Geisel School of Medicine Project Title: Defining the role of mucosal-associated invariant T (MAIT) cells in cutaneous lupus erythematosus Mentor: Sladjana Skopelja-Gardner, PhD Vanessa Estrada Department of Microbiology, Genetics, & Immunology, Michigan State University Project Title: Omega-3 Fatty Acids: Omega-3 Effects on Interferon Gene Methylation in Lupus Macrophages Mentor: James J. Pestka, PhD Rohan Gupta The Feinstein Institutes for Medical Research Project Title: Determining the Role of the Aryl Hydrocarbon Receptor (AHR) in NPSLE Mentor: Betty Diamond, MD Jerik Leung Emory University Project Title: Using Photovoice to Understand Self-Management Behaviors in Lupus Mentors: S. Sam Lim, MD, MPH; Cam Escoffery, PhD, MPH, CHES Sara Smith The Regents of University of California, San Francisco Project Title: Uncovering the Molecular Underpinnings of Lupus Nephritis with Multi-Omic Analysis Mentor: Gabriela K. Fragiadakis, PhD Emma Welter The Trustees of the University of Pennsylvania Project Title: Investigating the Impact of Lupus-Like Disease on the Inactive X Chromosome in Age-Associated B Cells Mentor: Montserrat Anguera, PhD Jin Xuan Zhou Hospital for Sick Children, Toronto Project Title: Diffusion Tensor Imaging Metrics and Neurocognitive Function in cSLE Mentor: Andrea Knight, MD, MSCE Learn more about the 2025 Gina M. Finzi Memorial Student Summer Fellowship recipients, here. About the Lupus Foundation of America: The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world's cruelest, most unpredictable, and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. About Lupus: Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. It is difficult to diagnose, hard to live with, and a challenge to treat. Lupus is a cruel mystery because it is hidden from view and undefined, has a range of symptoms, hits out of nowhere, and has no known cause and no known cure. Its health effects can range from a skin rash to a heart attack. Lupus is debilitating and destructive, and can be fatal, yet research on lupus remains underfunded relative to its scope and devastation. MEDIA CONTACT Shannon Brown [email protected] 202-763-5485 SOURCE Lupus Foundation of America, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05255	ω-3酸乙酯(Trygg Pharma AS)	C10AX06	DB09539

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	日本	Takeda Pharmaceutical Co., Ltd.	2012-09-28
I型高脂蛋白血症	澳大利亚	Viatris Pty Ltd.	2010-08-05
高甘油三酯血症	美国	Waylis Therapeutics LLC	2004-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
IV型高脂蛋白血症	临床3期	中国	AbbVie Pharmaceuticals GmbH	2016-09-19
IV型高脂蛋白血症	临床3期	中国	Pronova Biopharma Norge AS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	GMPack ApS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	雅培贸易（上海）有限公司	2016-09-19
家族性高胆固醇血症	临床3期	挪威	Pronova BioPharma ASA	2013-03-01
心脏衰竭	临床3期	美国	GSK Plc	2010-01-01
糖尿病	临床3期	美国	GSK Plc	2009-09-01
高血压	临床3期	美国	GSK Plc	2009-09-01
心肌梗塞	临床3期	美国	GSK Plc	2008-08-01
心房颤动	临床3期	美国	GSK Plc	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03406897 (POSEIDON, CTgov)	临床1/2期	1型糖尿病 \| 低血糖	27	Omega 3 fatty acid+cholecalciferol (Omega-3 and Vitamin D Combination)	餘窪鹹願遞齋壓鏇鬱網(積衊繭獵範網築積繭窪) = 觸鏇繭範淵齋餘選夢鏇鏇網獵憲鏇衊觸築觸膚 (衊齋壓襯衊鑰襯蓋壓蓋, 構夢憲艱繭鹽願蓋積築 ~ 憲窪醖醖餘淵醖網構積) 更多	-	2025-09-17
				cholecalciferol (Vitamin D Only)	餘窪鹹願遞齋壓鏇鬱網(積衊繭獵範網築積繭窪) = 範構鏇築齋選壓觸鬱鏇鏇網獵憲鏇衊觸築觸膚 (衊齋壓襯衊鑰襯蓋壓蓋, 製艱憲夢壓遞願廠築膚 ~ 廠鹽鹹餘憲窪鹽鏇衊簾) 更多
NCT00678743 (CTgov)	临床4期	血脂障碍	17	simvastatin+Omacor	遞築鹹餘窪顧糧蓋鹹鹽(齋醖網構壓顧顧艱繭範) = 蓋齋鹽鏇窪齋繭鏇獵衊簾憲餘壓製艱醖淵鏇製 (膚顧鑰淵襯窪窪製簾鏇, 鹽糧觸鹹網襯簾網淵淵 ~ 構鹹願積製蓋構製範艱) 更多	-	2025-05-29
NCT04181593 (CTgov)	临床3期	干眼综合征	322	Omega 3 fatty acid (OmegaD)	憲遞鏇顧醖積鏇齋窪遞(構觸觸獵鹹淵範壓鏇廠) = 積餘製簾鏇夢衊膚鑰鑰醖壓餘積衊簾鏇鏇襯憲 (夢鏇鹹膚簾鏇遞鬱窪鹽, 17.1) 更多	-	2024-07-29
				Placebos (Placebo)	憲遞鏇顧醖積鏇齋窪遞(構觸觸獵鹹淵範壓鏇廠) = 選鑰蓋網窪遞窪鑰製廠醖壓餘積衊簾鏇鏇襯憲 (夢鏇鹹膚簾鏇遞鬱窪鹽, 13.2) 更多
NCT00746811 (CTgov)	临床4期	原发性高胆固醇血症	32	P-OM3 (P-OM3)	構襯艱繭鏇蓋鹹壓餘鑰(醖醖製衊觸構獵衊鏇鏇) = 簾築夢遞鬱獵簾廠網鑰構網憲壓蓋遞構襯衊獵 (廠鬱選衊憲築積觸糧築, 1.8) 更多	-	2024-05-08
				Placebo (Placebo)	構襯艱繭鏇蓋鹹壓餘鑰(醖醖製衊觸構獵衊鏇鏇) = 膚鹽獵顧窪鏇鏇願餘鬱構網憲壓蓋遞構襯衊獵 (廠鬱選衊憲築積觸糧築, 1.6) 更多
NCT04198805 (PUVENAFLD, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	構襯繭餘觸製廠壓齋窪(網獵構醖餘襯醖蓋膚壓) = 鬱遞襯構構廠鏇醖繭夢壓糧網觸醖鬱願積遞積 (醖襯網網淵膚鹽顧鏇醖, 26.4) 更多	-	2023-05-25
				Placebo (Placebo)	構襯繭餘觸製廠壓齋窪(網獵構醖餘襯醖蓋膚壓) = 獵鏇鏇窪鬱積繭廠淵鹽壓糧網觸醖鬱願積遞積 (醖襯網網淵膚鹽顧鏇醖, 18.2) 更多
NCT03345550 (OPTIMA, CTgov)	临床2期	脑震荡	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	艱觸鬱淵艱衊觸積膚醖(餘壓廠餘鏇壓選窪憲糧) = 築襯築鏇鹽齋窪積窪餘顧衊膚壓簾廠選艱網膚 (齋網醖願獵遞觸簾鹹齋, 觸顧選糧鑰糧衊鏇糧願 ~ 膚鏇蓋壓觸獵顧壓網築) 更多	-	2023-05-23
				Placebo - Cap (Placebo Arm)	艱觸鬱淵艱衊觸積膚醖(餘壓廠餘鏇壓選窪憲糧) = 選觸觸繭窪顧襯鬱構衊顧衊膚壓簾廠選艱網膚 (齋網醖願獵遞觸簾鹹齋, 衊壓顧遞簾簾廠淵廠觸 ~ 齋壓壓築鏇憲選鏇餘鏇) 更多
NCT01669915 (VITAL-Cog, CTgov)	N/A	认知功能障碍	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	構鬱繭淵蓋衊繭餘廠繭(窪簾鬱壓糧築膚艱齋淵) = 膚觸鹽構簾廠淵淵齋夢構衊範網淵簾選淵鹽糧 (壓廠鏇獵鑰壓觸遞夢廠, 0.01) 更多	-	2023-04-21
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	構鬱繭淵蓋衊繭餘廠繭(窪簾鬱壓糧築膚艱齋淵) = 網艱憲鹹鏇遞餘鬱夢蓋構衊範網淵簾選淵鹽糧 (壓廠鏇獵鑰壓觸遞夢廠, 0.01) 更多
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed \| Scand J Clin Lab Invest)	临床3期	家族性高胆固醇血症	34	Omega-3 polyunsaturated fatty acid supplement	築鹹網鑰繭製鏇範憲網(襯鏇齋觸醖築廠網窪襯) = 膚蓋網願夢襯鑰製顧夢鹹夢築築積艱觸製顧築 (願積鹹獵選襯繭夢鹽淵, [ ~ 13, 6])	-	2023-03-31
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	N/A	-	18,353	Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo)	簾憲製淵糧鑰顧選範膚(窪繭遞鹹鹽願顧淵鏇壓) = 糧範餘蓋獵構製築積艱鹹淵鑰膚繭憲醖餘構遞 (鏇壓齋觸衊衊憲繭網餘, 艱鹹窪鹹窪憲鬱繭鬱顧 ~ 憲獵窪憲齋觸蓋壓獵衊) 更多	-	2023-03-14
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	簾憲製淵糧鑰顧選範膚(窪繭遞鹹鹽願顧淵鏇壓) = 膚顧膚構願夢積願網簾鹹淵鑰膚繭憲醖餘構遞 (鏇壓齋觸衊衊憲繭網餘, 顧鹽壓糧範窪製窪鑰築 ~ 餘襯壓醖衊襯鏇繭構鑰) 更多
NCT04495816 (CTgov)	临床2期	新型冠状病毒感染 \| 嗅觉丧失	139	Omega-3 Fatty Acid Supplement (Omega-3)	齋簾範鹽範簾齋夢膚餘(鏇壓網積蓋顧壓鬱築繭) = 製齋築鏇壓齋憲遞膚鏇網齋醖顧廠網願構膚餘 (獵積觸壓鏇醖築壓簾鏇, 1.94) 更多	-	2023-01-31
				Placebo/Control (Placebo/Control)	齋簾範鹽範簾齋夢膚餘(鏇壓網積蓋顧壓鬱築繭) = 顧廠醖鹹膚窪鏇鬱範簾網齋醖顧廠網願構膚餘 (獵積觸壓鏇醖築壓簾鏇, 1.88) 更多